# Phase 1, Dose Escalation Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SM04690 in Moderate to Severe Knee Osteoarthritis (OA)

> **NCT02095548** · PHASE1 · COMPLETED · sponsor: **Biosplice Therapeutics, Inc.** · enrollment: 61 (actual)

## Conditions studied

- Moderate to Severe Osteoarthritis

## Interventions

- **DRUG:** SM04690, 0.03mg/2mL
- **DRUG:** SM04690, 0.07mg/2mL
- **DRUG:** SM04690, 0.23mg/2mL
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02095548
- **Lead sponsor:** Biosplice Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-03
- **Primary completion:** 2015-09
- **Final completion:** 2015-09
- **Target enrollment:** 61 (ACTUAL)
- **Last updated:** 2015-12-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02095548

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02095548, "Phase 1, Dose Escalation Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SM04690 in Moderate to Severe Knee Osteoarthritis (OA)". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT02095548. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*